Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALNY
Previous Symbol
CUSIP02043Q10
Phone617-551-8200
Debt
Debt-to-Equity Ratio0.02
Current Ratio11.05
Quick Ratio10.96
Price-To-Earnings
Trailing P/E Ratio-14.23
Forward P/E Ratio-9.90
P/E GrowthN/A
Sales & Book Value
Annual Sales$89.91 million
Price / Sales86.67
Cash FlowN/A
Price / Cash FlowN/A
Book Value$17.96 per share
Price / Book4.29
Profitability
EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-754.13%
Return on Equity-43.07%
Return on Assets-38.62%
Miscellaneous
Employees749
Outstanding Shares101,030,000
Market Cap$8.03 billion
OptionableOptionable
Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions
What is Alnylam Pharmaceuticals' stock symbol?
Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."
How were Alnylam Pharmaceuticals' earnings last quarter?
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks' consensus estimate of ($2.02) by $0.41. The biopharmaceutical company had revenue of $2.07 million for the quarter, compared to analyst estimates of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 43.07% and a negative net margin of 754.13%. The company's revenue for the quarter was down 87.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.34) EPS. View Alnylam Pharmaceuticals' Earnings History.
When is Alnylam Pharmaceuticals' next earnings date?
What price target have analysts set for ALNY?
15 analysts have issued 1 year price targets for Alnylam Pharmaceuticals' shares. Their forecasts range from $63.00 to $230.00. On average, they anticipate Alnylam Pharmaceuticals' share price to reach $140.80 in the next year. This suggests a possible upside of 82.5% from the stock's current price. View Analyst Price Targets for Alnylam Pharmaceuticals.
What is the consensus analysts' recommendation for Alnylam Pharmaceuticals?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alnylam Pharmaceuticals.
What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and 12-mo. $135 PT. Alnylam hosted an R&D day Thursday, where pipeline updates and long-term strategy were largely in line with our recently published expectations here. With three Ph3 readouts and two potential NDA filings in 2019 alone, we think ALNY is well on its way to establishing itself as a diversified global commercial biotech company, if pipeline execution continues. We see many late and mid-stage readouts over the next 12 months that will help ALNY build more commercial and mid/late- stage products (see p. 2). ALNY will preannounce 4Q18 Onpattro sales in early Jan. 2019." (12/7/2018)
- 2. According to Zacks Investment Research, "Although we are pleased with Alnylam’s broad and promising pipeline, we note that most candidates are in their early or mid stages of development. These candidates still have a long way to go before hitting the market. Currently, Alnylam depends heavily on Onpattro for growth. We also note that gaining approval for pipeline candidates has become more difficult now. However, In August, Alnylam got a significant boost with the approval of Onpattro (patisiran), a first-of-its-kind RNA interference (RNAi) therapeutic, both in the United States and in Europe, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This is the first approved candidate for the company and hence should drive revenues. Loss estimates have remained stable ahead of the Q3 earnings release." (10/8/2018)
- 3. Needham & Company LLC analysts commented, "Alnylam is expected to announce results of an interim analysis of the Phase 3 trial of givosiran in Acute Hepatic Porphyrias (AHP) later this month. The FDA has reportedly indicated that a statistically significant reduction in biomarker urine ALA level w/ the first 30 enrolled patients may be sufficient for accelerated approval. We expect a positive outcome based on strength of data collected from Phase 1/2 testing, in which profound and durable reductions in urine ALA levels were observed. Mgmt has guided for NDA submission by YE18. We assume U.S. commercial launch in 2H19 and WW peak sales $600-700M. Reiterate BUY." (9/13/2018)
- 4. BMO Capital Markets analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. Revance remains on track to report results from the long-term safety study (SAKURA 3) of RT-002 in glabellar lines in 4Q18. Following this, Revance is expected to file its BLA for RT-002 in glabellar lines in 1H19. We continue to see RT-002 as a differentiated long duration neurotoxin that has the potential to seriously challenge the current market order." (8/3/2018)
Has Alnylam Pharmaceuticals been receiving favorable news coverage?
News articles about ALNY stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alnylam Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the stock's share price in the near term.
Who are some of Alnylam Pharmaceuticals' key competitors?
Some companies that are related to Alnylam Pharmaceuticals include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC) and Beigene (BGNE).
Who are Alnylam Pharmaceuticals' key executives?
Alnylam Pharmaceuticals' management team includes the folowing people:
- Dr. John M. Maraganore, CEO & Exec. Director (Age 55)
- Mr. Barry E. Greene, Pres (Age 55)
- Mr. Manmeet Singh Soni, Sr. VP ,CFO & Principal Accounting Officer (Age 40)
- Dr. Yvonne Greenstreet, Exec. VP & COO (Age 55)
- Dr. Akshay K. Vaishnaw, Pres of R&D (Age 55)
Who are Alnylam Pharmaceuticals' major shareholders?
Alnylam Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.53%), Vanguard Group Inc (7.53%), BlackRock Inc. (6.04%), Dodge & Cox (4.61%) and Dodge & Cox (4.61%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.
Which institutional investors are selling Alnylam Pharmaceuticals stock?
ALNY stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Point72 Asset Management L.P., Renaissance Technologies LLC, Deutsche Bank AG, Kornitzer Capital Management Inc. KS, Los Angeles Capital Management & Equity Research Inc., Sphera Funds Management LTD. and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.
Which institutional investors are buying Alnylam Pharmaceuticals stock?
ALNY stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, TIAA CREF Investment Management LLC, Baillie Gifford & Co., BB Biotech AG, The Manufacturers Life Insurance Company , American Century Companies Inc., Bellevue Group AG and Candriam Luxembourg S.C.A.. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.
How do I buy shares of Alnylam Pharmaceuticals?
Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alnylam Pharmaceuticals' stock price today?
One share of ALNY stock can currently be purchased for approximately $77.13.
How big of a company is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals has a market capitalization of $8.03 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.
What is Alnylam Pharmaceuticals' official website?
How can I contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]
MarketBeat Community Rating for Alnylam Pharmaceuticals (NASDAQ ALNY)
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
